telitacicept
telitacicept: developed by 1 company · 4 clinical trials tracked.
telitacicept evidence translation
What we can confirm
4 tracked trials
What it means
What to watch
Prepared research question
How could telitacicept → VOR affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence4 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Vor Biopharma Inc. (VOR) Generalized Myasthenia Gravis; Primary Sjogren's Disease | Phase 3 |
Clinical Trials (4)
Treatment Strategy for Patients With Rheumatoid Arthritis Associated Interstitial Lung Disease
Primary endpoint: Change in FVC from baseline to week 52
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Telitacicept in Adult Participants With Active Primary Sjögren's Disease
Primary endpoint: To evaluate the efficacy of telitacicept versus placebo at Week 48 in the change from baseline in the EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) score at Week 48.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study With an Open-label Extension Period to Evaluate the Efficacy and Safety of Telitacicept in Patients With Generalized Myasthenia Gravis
Primary endpoint: Change from baseline in Myasthenia Gravis-Activities of Daily Living (MG-ADL) score at Week 24
A Randomized, Double-blind Placebo-controlled Study of Recombinant Human B Lymphocyte Stimulating Factor Receptor-Fc Fusion Protein for the Treatment of Connective Tissue Disease-associated Thrombocytopenia
Primary endpoint: Overall response (CR + PR) rate
Frequently asked questions
Who is developing telitacicept?
telitacicept is being developed by Vor Biopharma Inc..
How many clinical trials involve telitacicept?
BioSniper tracks 4 clinical trials involving telitacicept.